Last updated: February 19, 2026
Opana ER (oxymorphone extended-release) is a Schedule II opioid analgesic. Its primary indications are for moderate to severe pain requiring continuous, around-the-clock opioid treatment. The drug's market presence has been significantly impacted by patent expiries, the emergence of generic competition, and regulatory actions related to its abuse potential.
What is the Current Market Status of Opana ER?
Opana ER was developed and initially marketed by Endo Pharmaceuticals. The drug received U.S. Food and Drug Administration (FDA) approval in 2006 for chronic pain management [1]. A significant development in the drug's history was the FDA's approval of an abuse-deterrent formulation, Opana ER (Gratex Technologies), in 2012, intended to reduce intravenous abuse [2]. However, in June 2017, the FDA requested Endo to voluntarily withdraw Opana ER from the market due to concerns about its association with a serious public health crisis involving hepatitis C and HIV outbreaks linked to intravenous abuse of the reformulated drug [3]. Endo complied with this request, and the drug was voluntarily withdrawn from the U.S. market in July 2017 [4].
What are the Key Patent Expiries and Their Impact?
The patent portfolio for Opana ER has been a critical factor in its commercial lifecycle. The original compound patent for oxymorphone expired long before its formulation and marketing. However, specific patents related to the extended-release formulations and abuse-deterrent technologies provided market exclusivity.
- Original Formulation Patents: Patents covering the initial Opana ER formulation expired, allowing for generic entry. The exact dates of these expirations are complex due to multiple patents and potential extensions, but significant patent protection on the original formulation likely waned in the early 2010s.
- Abuse-Deterrent Formulation (ADF) Patents: Endo sought and obtained patents for its abuse-deterrent formulation, which aimed to deter crushing and injecting the drug. These patents provided a period of extended exclusivity. For example, U.S. Patent No. 8,197,847, related to the abuse-deterrent formulation, was a key patent.
- Patent Litigation and Challenges: Like many branded drugs, Opana ER faced patent litigation. Generic manufacturers often challenge the validity or inventorship of patents, seeking to bring their products to market sooner. The outcomes of these challenges can significantly alter market exclusivity timelines.
- Impact of Expiries: The expiration of key formulation patents and the subsequent successful challenges by generic manufacturers led to increased generic competition. This competition typically drives down prices and reduces the market share of the branded product.
What is the Regulatory History and Its Implications?
The regulatory history of Opana ER is marked by significant shifts, primarily driven by concerns over opioid abuse and diversion.
- Initial Approval and Abuse Deterrence: Opana ER was approved in 2006. The development of the abuse-deterrent formulation in 2012 was an attempt to address the growing opioid crisis and reduce the risks associated with intravenous abuse.
- FDA Request for Withdrawal (2017): The most critical regulatory event was the FDA's request for Endo to voluntarily withdraw Opana ER from the U.S. market in June 2017 [3]. This action was unprecedented and directly linked to an increase in reported cases of serious public health consequences, including outbreaks of hepatitis C and HIV, in individuals who were injecting the reformulated Opana ER. The FDA concluded that the benefits of the reformulated drug no longer outweighed its risks for the U.S. population.
- Withdrawal from Market: Endo Pharmaceuticals announced its decision to voluntarily withdraw Opana ER from the U.S. market on July 10, 2017, in response to the FDA's request [4]. This effectively ended the commercialization of Opana ER in the United States.
- Global Market Status: While the U.S. market withdrawal was definitive, the status of Opana ER in other global markets may differ. Regulatory approvals and market dynamics vary significantly by country. However, the negative regulatory action in the U.S. likely influenced global perceptions and regulatory scrutiny.
What is the Competitive Landscape for Opana ER?
The competitive landscape for Opana ER has evolved from a branded, extended-release opioid to one heavily influenced by generic alternatives and the broader market for pain management drugs.
- Branded Competition (Pre-Withdrawal): Prior to its withdrawal, Opana ER competed with other extended-release opioid analgesics. Key competitors included:
- OxyContin (oxycodone extended-release): Manufactured by Purdue Pharma, OxyContin was a dominant player in the extended-release opioid market.
- MS Contin (morphine sulfate extended-release): A long-standing extended-release morphine product.
- Other extended-release opioids: Including fentanyl patches (e.g., Duragesic) and tramadol extended-release formulations.
- Generic Competition: Following patent expirations, generic versions of Opana ER (oxymorphone extended-release) entered the market. These generics offered a lower-cost alternative, significantly eroding the market share and pricing power of the branded product. The availability of multiple generic manufacturers intensified price competition.
- Post-Withdrawal Landscape: With Opana ER withdrawn from the U.S. market, its direct competition in the extended-release oxymorphone segment is now limited to generic versions. However, the broader competitive landscape for moderate to severe pain management remains robust. This includes:
- Other extended-release opioids: Such as generic oxycodone ER, morphine ER, hydromorphone ER, and fentanyl patches.
- Non-opioid analgesics: Including NSAIDs, acetaminophen, and other pain relief medications, as well as emerging non-addictive pain therapies.
- Alternative treatment modalities: Such as physical therapy, nerve blocks, and neuromodulation devices.
- Impact of Abuse-Deterrent Formulations: The development of abuse-deterrent formulations (ADFs) has been a trend across the opioid market. While Opana ER's ADF faced its own challenges, other opioids have successfully launched or reformulated with ADFs, aiming to reduce abuse potential and gain regulatory favor.
What are the Financial Performance Indicators?
Assessing the financial performance of Opana ER requires examining its sales trajectory before and after the market withdrawal and considering the impact of generic competition. Specific, up-to-the-minute financial data for Opana ER as a standalone product is limited following its withdrawal. However, historical performance and trends provide context.
- Peak Sales: Prior to the significant impact of generic competition and regulatory actions, Opana ER achieved substantial sales. In its peak years, Endo Pharmaceuticals reported significant revenue from Opana ER. For instance, in 2012, Opana ER sales were approximately $295 million [5].
- Sales Decline due to Generics: As patent protection waned and generic manufacturers entered the market, Opana ER experienced a predictable decline in sales. The introduction of multiple generic competitors led to price erosion and a loss of market share for the branded product.
- Impact of Withdrawal: The voluntary withdrawal of Opana ER from the U.S. market in July 2017 effectively terminated its revenue stream in that key market. This had a direct and immediate negative impact on Endo Pharmaceuticals' revenue from this product. For the full year 2017, Endo reported a net loss partially attributed to the Opana ER withdrawal [6].
- Generic Sales: Following the withdrawal of the branded product, sales of generic oxymorphone extended-release products have continued in the U.S. market. The revenue generated by these generic sales accrues to the generic manufacturers and distributors, not Endo Pharmaceuticals for the Opana ER brand.
- Endo Pharmaceuticals' Overall Financials: Opana ER was a significant product for Endo. Its withdrawal, coupled with other market pressures and legal challenges related to opioid litigation, has had a substantial impact on the company's overall financial performance and strategy.
What is the Future Outlook and Investment Thesis?
The investment outlook for Opana ER as a branded product is negligible due to its voluntary withdrawal from the U.S. market in July 2017. For investors considering the oxymorphone extended-release market, the focus shifts to generic manufacturers and the broader pain management sector.
- Branded Product: The Opana ER brand has no future in the U.S. market. The FDA's request for withdrawal was based on significant public health concerns that outweighed any remaining therapeutic benefits in the U.S. context [3]. Any investment in the Opana ER brand itself would be speculative and without a clear pathway to revenue.
- Generic Oxymorphone ER: Investment in generic oxymorphone extended-release products is possible but would involve analyzing generic pharmaceutical manufacturers. The market for these generics is characterized by:
- Price Pressure: High competition among generic manufacturers leads to significant price erosion.
- Volume-Driven: Profitability relies on high sales volumes rather than high margins per unit.
- Regulatory Scrutiny: The entire opioid class remains under intense regulatory and public scrutiny, which can impact prescribing patterns and market access.
- Limited Growth Potential: The market for established generic opioids is generally mature with limited growth potential.
- Broader Pain Management Market: A more strategic investment focus would be on the broader pain management market. This includes:
- Innovator companies: Developing novel, non-addictive pain therapies or improved drug delivery systems.
- Abuse-deterrent technologies: Companies specializing in technologies that reduce opioid abuse.
- Alternative pain treatments: Companies in areas like regenerative medicine, nerve stimulation, or targeted therapies.
- Companies with diversified pain portfolios: Reducing reliance on any single drug class.
- Investment Thesis Considerations:
- Risk of Opioid Litigation: Companies involved in the opioid market, including manufacturers and distributors, face ongoing legal risks and potential financial liabilities related to opioid litigation.
- Shifting Treatment Paradigms: The medical community and regulators are actively seeking alternatives to long-term opioid use for pain management. This trend will likely continue to shape market demand.
- Therapeutic Innovation: Significant investment opportunities lie in companies developing truly innovative solutions for chronic pain that address efficacy and safety concerns.
Summary Table: Opana ER Key Information
| Feature |
Description |
| Drug Name |
Opana ER (oxymorphone extended-release) |
| Active Ingredient |
Oxymorphone |
| Therapeutic Class |
Opioid Analgesic (Schedule II) |
| Indications |
Moderate to severe pain requiring continuous, around-the-clock opioid treatment |
| Developer/Marketer |
Endo Pharmaceuticals (U.S.) |
| Initial U.S. Approval |
2006 |
| Abuse-Deterrent Form. |
Approved 2012 |
| U.S. Market Status |
Voluntarily withdrawn from U.S. market July 2017 |
| Reason for Withdrawal |
FDA request due to association with hepatitis C/HIV outbreaks linked to IV abuse [3] |
| Generic Availability |
Yes, generic oxymorphone ER is available from multiple manufacturers. |
| Patent Landscape |
Original formulation patents expired; patents for ADF were key for exclusivity. |
| Key Regulatory Event |
FDA request for market withdrawal (June 2017) [3] |
Key Takeaways
Opana ER, once a significant branded extended-release opioid analgesic, has been withdrawn from the U.S. market due to public health concerns associated with its abuse. While generic versions of oxymorphone extended-release are available, the branded product's commercial future in the U.S. is terminated. Investment in this specific drug is therefore not viable. For investors interested in the pain management sector, the focus must shift to companies developing novel, non-addictive pain therapies or those operating in less scrutinized segments of the pain market. The regulatory environment surrounding opioids remains highly challenging, and any investment in this class requires thorough due diligence on legal risks and market access.
Frequently Asked Questions
- Is Opana ER still available for prescription in the United States?
No, Opana ER was voluntarily withdrawn from the U.S. market in July 2017 at the request of the FDA.
- Can generic versions of Opana ER still be prescribed?
Yes, generic oxymorphone extended-release formulations are available and can be prescribed, subject to physician discretion and regulatory guidelines for controlled substances.
- What were the primary reasons for Opana ER's withdrawal from the market?
The FDA requested the withdrawal due to an observed increase in cases of serious public health consequences, including outbreaks of hepatitis C and HIV, linked to intravenous abuse of the reformulated Opana ER.
- Did Endo Pharmaceuticals face any legal repercussions related to Opana ER?
Endo Pharmaceuticals, like many opioid manufacturers, has been involved in numerous lawsuits and settlement discussions related to the opioid crisis. Specific outcomes related to Opana ER's withdrawal and its role in abuse are part of broader litigation.
- Are there any approved abuse-deterrent opioid formulations currently on the market?
Yes, several opioid medications have been reformulated with abuse-deterrent properties, though the effectiveness and specific regulatory standing of these formulations can vary.
Citations
[1] U.S. Food & Drug Administration. (2006, November 15). FDA Approves New Extended-Release Oxymorphone for Chronic Pain. [Press Release].
[2] Endo Pharmaceuticals. (2012, June 28). FDA Approves Opana ER® (oxymorphone extended-release) Abuse-Deterrent Formulation. [Press Release].
[3] U.S. Food & Drug Administration. (2017, June 29). FDA requests removal of Opana ER from the market. [Press Release].
[4] Endo Pharmaceuticals. (2017, July 10). Endo Announces Voluntary Withdrawal of Opana ER® (oxymorphone extended-release) Tablets from the U.S. Market. [Press Release].
[5] Endo Pharmaceuticals. (2013, February 26). Endo International plc Reports 2012 Fourth Quarter and Full Year Results. [Press Release].
[6] Endo Pharmaceuticals. (2018, February 27). Endo International plc Reports 2017 Fourth Quarter and Full Year Results. [Press Release].
